BJMO - volume 6, issue 4, september 2012
T. Feys MBA, MSc
EORTC 90101 CREATE assesses the antitumour activity and safety of crizotinib across predefined tumour types in patients whose tumours are possibly harbouring specific alterations in ALK and/or MET. (BELG J MED ONCOL 2012;6:129–131)
Read moreBJMO - volume 6, issue 3, june 2012
No authors
(BELG J MED ONCOL 2012;6:102–103)
Read moreBJMO - volume 6, issue 2, april 2012
No authors
(BELG J MED ONCOL 2012;6:63–69)
Read moreBJMO - volume 6, issue 1, february 2012
No authors
(BELG J MED ONCOL 2012;6:26–36)
Read more
Top
